DIVISLAB vs SUNPHARMA
Head-to-head DCF comparison · Divi's Laboratories Limited vs Sun Pharmaceutical Industries
Model Favors
SUNPHARMA shows a larger model margin of safety
Leads on 4 of 4model metrics · not investment advice
DIVISLAB
Divi's Laboratories Limited
Pharma
₹6,268
OvervaluedSUNPHARMA
Sun Pharmaceutical Industries
Pharma
₹1,665
Fairly Valued| Metric | DIVISLAB | SUNPHARMA |
|---|---|---|
| Verdict | Overvalued | Fairly Valued |
| YieldIQ Score | 43/100 | 74/100 |
| Fair Value | ₹2,520 | ₹1,860 |
| Current Price | ₹6,268 | ₹1,665 |
| Margin of Safety | -59.8% | +11.7% |
| Moat | Narrow | Wide |
| Piotroski F-Score | 6/9 | 9/9 |
| ROE | 14.6% | — |
| Debt / Equity | — | 0.07 |
| EV / EBITDA | 46.9× | 23.6× |
| Market Cap | ₹1.66 Lakh Cr | ₹4.00 Lakh Cr |
Run the full interactive analysis
DCF sliders, sensitivity tables, peer screens, watchlists — free to start.
Sign up free →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst.